CPC C07K 16/2896 (2013.01) [A61K 39/3955 (2013.01); A61K 47/6849 (2017.08); C07K 16/28 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); C07K 2317/21 (2013.01); C07K 2317/33 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] | 9 Claims |
1. A method of treating goblet cell metaplasia and/or excess mucus, the method comprising administering to a subject in need thereof an effective amount of an antibody that binds to human Jagged2, wherein the antibody comprises:
a) amino acid residues 31-35 of SEQ ID NO: 88 as CDRH1, amino acid residues 50-65 of SEQ ID NO: 88 as CDRH2, amino acid residues 95-102 of SEQ ID NO: 88 as CDRH3, amino acid residues 24-34 of SEQ ID NO: 100 as CDRL1, amino acid residues 50-56 of SEQ ID NO: 100 as CDRL2, and amino acid residues 89-97 of SEQ ID NO: 100 as CDRL3;
b) amino acid residues 31-35 of SEQ ID NO: 89 as CDRH1, amino acid residues 50-65 of SEQ ID NO: 89 as CDRH2, amino acid residues 95-102 of SEQ ID NO: 89 as CDRH3, amino acid residues 24-34 of SEQ ID NO: 101 as CDRL1, amino acid residues 50-56 of SEQ ID NO: 101 as CDRL2, and amino acid residues 89-97 of SEQ ID NO: 101 as CDRL3;
c) amino acid residues 31-35 of SEQ ID NO: 90 as CDRH1, amino acid residues 50-65 of SEQ ID NO: 90 as CDRH2, amino acid residues 95-102 of SEQ ID NO: 90 as CDRH3, amino acid residues 24-34 of SEQ ID NO: 102 as CDRL1, amino acid residues 50-56 of SEQ ID NO: 102 as CDRL2, and amino acid residues 89-97 of SEQ ID NO: 102 as CDRL3; or
d) amino acid residues 31-35 of SEQ ID NO: 91 as CDRH1, amino acid residues 50-65 of SEQ ID NO: 91 as CDRH2, amino acid residues 95-102 of SEQ ID NO: 91 as CDRH3, amino acid residues 24-34 of SEQ ID NO: 103 as CDRL1, amino acid residues 50-56 of SEQ ID NO: 103 as CDRL2, and amino acid residues 89-97 of SEQ ID NO: 103 as CDRL3,
wherein the amino acid residue numbering is according to Kabat, and
wherein the goblet cell metaplasia and/or excess mucus is associated with asthma or chronic obstructive pulmonary disease (COPD).
|